PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Testosterone - Transgender Health - Children & Young People
PAD Profile : Testosterone - Transgender Health - Children & Young People
Keywords :
gender reassignment, gender re-assignment, gender identity clinics, GICs, gender incongruence, sex change, transgender, hormonal therapy, masculinisation, transsexuals, hormonal treatment, gender dysphoria
Brand Names Include :
Tostran, Testogel, Sustanon 250
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
Other Indications
Additional Documents
Type
Document
Review Date
Guidelines (Local)
01 June 2027
Committee Recommendations
Date
Committee Name
Narrative
05 June 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
With the publication of the final Cass Report and new NHSE commissioning policies, the APC has agreed an AMBER status for gender affirming hormones in children and young people. This applies to recommendations from both NHS and private providers subject to appropriate shared care protocols being in place.
The following guidance has also been updated:
- Primary care prescribing guidance, for people who access Gender Identity Services.
- NHSE guidance on prescribing and dispensing restrictions for puberty blockers and gender affirming hormones
07 February 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Integrated Health System Area Prescribing Committee (APC) has agreed that topical testosterone should be prescribed generically, ideally using Drug Tariff descriptions.
Associated BNF Codes
06. Endocrine System
06.04.02. Male sex hormones and antagonists